Cytomedix, Inc. (NYSE Amex:GTF) Registered Direct Offering
ROCKVILLE, Md., Aug. 27, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) ("the Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced it entered into securities purchase agreements with investors to raise gross proceeds of approximately $420,000, before placement agent's fees and other offering expenses, in a registered direct offering. This represents the second and final tranche to the financing previously announced on August 12, 2009, which raised an initial approximate $1,050,000. The offering is expected to close on or about August 31, 2009. Proceeds will be used for general corporate purposes. Avalon Securities Ltd. acted as exclusive placement agent, on a "best efforts" basis, for this transaction.
Cytomedix develops, sells and licenses regenerative biological therapies including the AutoloGel (tm) System, a device for the production of Platelet Rich Plasma gel derived from the patient's own blood. The AutoloGel (tm) System is cleared by the U.S. Food and Drug Administration for use on a variety of exuding wounds. The Company is pursuing a multifaceted strategy to penetrate the chronic wound market with its AutoloGel (tm) System and is moving forward with the development of other product candidates in its pipeline. Most notably is its CT-112 product, an anti-inflammatory peptide that has shown promise in preclinical testing.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.
Cubic Energy Inc. (NYSE Amex:QBC)Unregistered Sale of Equity Securities
On August 18 and August 26, 2009, Cubic Energy, Inc. (the "Company") entered into Subscription and Registration Rights Agreements (the "Subscription Agreements") with certain investors (the "Investors"). Pursuant to the Subscription Agreements, the Company issued 804,000 shares of common stock on August 18, 2009, and 1,300,001 shares of common stock on August 26, 2009, for an aggregate of 2,104,001 shares. Avalon Securities Ltd. acted as exclusive placement agent, on a "best efforts" basis, for this transaction.
Pursuant to the Subscription Agreements, the Investors paid aggregate consideration of approximately $1,788,400 to the Company for 2,104,001 shares of the Company's common stock and warrants exercisable into 1,052,000 shares of common stock. The warrants are exercisable through July 31, 2014, at $0.85 per share. The shares and warrants were issued by the Company in reliance upon an exemption from registration set forth in Regulation D and/or Section 4(2) of the Securities Act of 1933, as amended. On September 1, 2009, the Company issued a press release with respect to this item.
About Avalon Group, Ltd.
Avalon Group, Ltd. provides clients access to the quality and technical expertise of a major investment bank while maintaining the confidential personal service and efficiency of a boutique firm. Our services include arranging private investments, registered direct offerings, and PIPEs, and providing fairness opinions, mergers and acquisitions, restructuring, and strategic advisory services. Since 1992, Avalon has worked with high caliber, committed corporate leaders to expand their business, re-capitalize or re-organize firms, sell or purchase divisions, and arrange liquidity events. Our clients have ranged from mid-market private companies to Fortune 500 companies to international entities and early stage firms. Avalon Group and Avalon Securities, its affiliated FINRA, SIPC and SEC registered broker-dealer, are located in mid-town Manhattan.
Avalon’s Capital Markets team offers capital raising and advisory services to public companies. As part of this process, we analyze our client’s operations to create solutions that are tailored to each client’s needs. We provide our clients with strategic introductions and access to institutional money managers, family offices, and high net worth individuals.